- Home
- LFT vs LXEO Comparison
LFT vs LXEO Comparison
Compare LFT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- LXEO
- Stock Information
- Founded
- LFT 2012
- LXEO 2017
- Country
- LFT United States
- LXEO United States
- Employees
- LFT N/A
- LXEO N/A
- Industry
- LFT Real Estate Investment Trusts
- LXEO
- Sector
- LFT Real Estate
- LXEO
- Exchange
- LFT Nasdaq
- LXEO Nasdaq
- Market Cap
- LFT 134.4M
- LXEO 140.6M
- IPO Year
- LFT N/A
- LXEO 2023
- Fundamental
- Price
- LFT $2.63
- LXEO $2.71
- Analyst Decision
- LFT Buy
- LXEO Strong Buy
- Analyst Count
- LFT 3
- LXEO 5
- Target Price
- LFT $2.50
- LXEO $22.20
- AVG Volume (30 Days)
- LFT 147.4K
- LXEO 1.4M
- Earning Date
- LFT 05-08-2025
- LXEO 05-08-2025
- Dividend Yield
- LFT 15.68%
- LXEO N/A
- EPS Growth
- LFT 18.59
- LXEO N/A
- EPS
- LFT 0.34
- LXEO N/A
- Revenue
- LFT $36,218,717.00
- LXEO N/A
- Revenue This Year
- LFT $172.71
- LXEO N/A
- Revenue Next Year
- LFT $0.46
- LXEO N/A
- P/E Ratio
- LFT $7.74
- LXEO N/A
- Revenue Growth
- LFT 12.91
- LXEO N/A
- 52 Week Low
- LFT $2.22
- LXEO $1.45
- 52 Week High
- LFT $2.84
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- LFT 52.67
- LXEO 48.48
- Support Level
- LFT $2.22
- LXEO $1.90
- Resistance Level
- LFT $2.64
- LXEO $2.64
- Average True Range (ATR)
- LFT 0.13
- LXEO 0.48
- MACD
- LFT 0.01
- LXEO 0.02
- Stochastic Oscillator
- LFT 93.18
- LXEO 51.43
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.